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Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like
protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC).
DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied
in the course of disease, data regarding DLL3 expression in relapses is not available.
The aim of this study was to investigate the expression of DLL3 in chemorelapsed
(but untreated with Rova-T) SCLC samples and compare the results with chemonaive
counterparts. Two evaluation methods to assess DLL3 expression were explored.
Additionally, we assessed if DLL3 expression of chemorelapsed and/or chemonaive
samples has prognostic impact and if it correlates with other clinicopathological data. The
study included 30 paired SCLC samples, which were stained with an anti DLL3 antibody.
DLL3 expression was assessed using tumor proportion score (TPS) and H-score and
was categorized as DLL3 low (TPS < 50%, H-score ≤ 150) and DLL3 high (TPS ≥ 50%,
H-score > 150). Expression data were correlated with clinicopathological characteristics.
Kaplan–Meier curves were used to illustrate overall survival (OS) depending on DLL3
expression in chemonaive and chemorelapsed samples, respectively, and depending
on dynamics of expression during course of therapy. DLL3 was expressed in 86.6%
chemonaive and 80% chemorelapsed SCLC samples without significant differences
between the two groups. However, the extent of expression varied in a substantial
proportion of pairs (36.6% with TPS, 43.3% with H-score), defined as a shift from low
to high or high to low expression. TPS and H-score provided comparable results. There
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were no profound correlations with clinicopathological data. Survival analysis revealed a
trend toward a more favorable OS in DLL low-expressing chemonaive SCLC (p = 0.57)
and, in turn, in DLL3 high-expressing chemorelapsed SCLC (p= 0.42) as well as in SCLC
demonstrating a shift from low to high expression (p = 0.56) without being statistically
significant. This is the first study to investigate DLL3 expression in a large cohort
of rare paired chemonaive-chemorelapsed SCLC specimens. Comparative analysis
revealed that DLL3 expression was not stable during the course of therapy, suggesting
therapy-based alterations. Unlike in chemonaive samples, a high DLL3 expression in
chemorelapsed samples indicated a trend for a more favorable prognosis. Our results
highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue.
Keywords: delta-like protein 3, small cell lung cancer, paired, chemonaive, chemorelapsed
INTRODUCTION
Small cell lung cancer (SCLC) is known as a highly aggressive
type of cancer with a miserable prognosis. It is the second
most common lung cancer type and accounts for ∼15% of
lung cancer cases. Therapy remained essentially unchanged in
recent years and is usually based on chemotherapy with etoposide
and a platinating agent (1), whereas, lately, clinical activity of
immunotherapies has been observed in patients with refractory
or metastatic SCLC. In a phase 3 trial conducted by Horn et al.
it was shown that the addition of the anti PD-L1 antibody
atezolizumab to chemotherapy in the first-line treatment of
extensive SCLC resulted in significantly longer overall survival
(OS) and progression-free survival than chemotherapy alone (2).
Almost all patients experience disease relapse within 3 months
(3). Although SCLC-targeted therapy research has progressed, in
contrast to non-small cell lung cancer (NSCLC) no personalized
targeted therapy options have been derived so far. Thus, further
research into the mechanism of SCLC and the exploration of new
therapeutic targets for SCLC are indispensable (4).
A new promising target is Delta-like protein 3 (DLL3),
a transmembrane protein found in most high-grade
neuroendocrine carcinomas of the lung, including SCLC.
Growing evidence supports a tumor-suppressor role for Notch-1
signaling in neuroendocrine tumors (5).
It is shown that the NOTCH receptor is mainly downregulated
by DLL3, thereby inhibiting the NOTCH signaling pathway
within the cell. Inactivation of Notch directs the lung stem cell
to a neuroendocrine precursor cell and contributes via biallelic
p53/RB loss to the onset of primary SCLC (6). In this context, the
achaete-scute homolog 1 (Ascl1) gene transcription factor plays a
major role. It controls crucial cellular mechanisms in SCLC such
as cell growth and survival. DLL3 expression is understood as a
direct downstream target of Ascl1, which interacts with the DLL3
gene promoter (7). This suggests that, during evolution of SCLC,
Notch1 is inactivated, and Ascl1 and DLL3 are both activated and
are, thus, counterparts to Notch1.
Abbreviations: Ascl1, Achaete-scute homolog 1; DLL3, Delta-like protein 3; IHC,
Immunohistochemistry; NSCLC, Non-small cell lung cancer; OS, overall survival;
Rova-T, Rovalpituzumab tesirine; SCLC, Small cell lung cancer; SI, staining
intensity; TPS, Tumor proportion score.
Therefore, one can assume that DLL3 could also be used
in cancer chemotherapy to target and suppress tumor cells (8).
Rovalpituzumab tesirine (Rova-T) is an antibody–drug conjugate
composed of SC16, a humanized IgG1 antibody against DLL3.
Rova-T selectively binds to DLL3 on target-expressing cells, is
internalized, and upon proteolytic cleavage, releases the toxin
pyrrolobenzodiazepine (PBD) leading to cell death (9).
In a phase I clinical trial, Rova-T was more effective in SCLC
with DLL3 overexpression (defined as expression in at least 50%
of cancer cells by immunohistochemistry) compared with SCLC
with a low level of DLL3 expression (5). Hence, DLL3 might be
a promising predictive marker for treatment of SCLC with Rova-
T (8). Rova-T is currently under development for patients with
SCLC positive for DLL3 (3).
Methods to evaluate DLL3 expression assessed via
immunohistochemistry are not standardized so far. In the
current study, the two applied methods (tumor proportion score
andH-score) were previously described in literature, including in
the above mentioned trial (5, 10) and compared with each other.
Although most SCLC recur after initial response to
chemotherapy, relapsed tumors are usually not biopsied.
The aim of our study was, therefore, to investigate the expression
of DLL3 on chemorelapsed SCLC samples and to compare its
expression to chemonaive counterparts. Differences in DLL3
expression between matched samples would suggest therapy-
associated changes in the tumor cells. In case of a loss of DLL3
expression in chemorelapsed SCLC samples one could assume
that a therapy with Rova-T is not promising. The results of the
study could be used to derive which material should be tested in
case of planned therapy with Rova-T in the recurrence situation.
MATERIALS AND METHODS
Cohort
In this multi-institutional retrospective study, tissue samples
from chemonaive SCLC and paired recurrent SCLC after
chemotherapy as well as from metastatic SCLC were collected.
The final cohort included 42 patients and consisted of 30 paired
chemonaive-chemorelapsed, 5 paired chemonaive primary-
metastatic, and 7 unpaired chemorelapsed SCLC without a
chemonaive counterpart. In the latter, from 3 patients, we had
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one sample each (only deriving from the primary site) and
from 4 patients, we had several (up to 4) samples deriving
from the primary site as well as from distant metastases (brain,
lymph node, adrenal, liver, bone, contralateral lung). In the
paired chemonaive-chemorelapsed subcohort, chemorelapsed
tissue derived from local recurrences in 10 cases, from distant
metastases in 19 cases (skin, brain, lymph node, bone, pleura,
pericardium, breast, pancreas), and in one case, the location
of the biopsied recurrent tumor was unknown. Chemonaive
metastatic samples derived from adrenals, bone, liver, pleura,
skin, and contralateral lung.
Patient Characteristics
The median age in the whole cohort was 63 years (range, 47–
83 y), 27 (64.3%) patients were male, 15 (35.7%), were female.
All patients received a platin-based chemotherapy, whereas
none of the patients had received therapy with Rova-T or
other therapeutic agents for example in the context of an
immunotherapy. Follow-up data for 33 out of the 42 patients
were available. From these, at time of last follow-up, 19 patients
were deceased, and 14 were alive. Samples from 4 patients derived
from autopsies. The basic clinicopathological data of our study
cohort are summarized in Table 1.
This study was approved by the internal review board of the
University of Luebeck (file number 16-277) and the respective
local ethical committees.
Statistical Analyses
For the statistical analyses and data visualization, R software
(version 4.0.2, R Foundation, Vienna, Austria; http://www.
R-project.org) was used. To investigate differences of DLL3
expression between the group of chemonaive and chemorelapsed
samples a Wilcoxon signed-rank test was used. To test if the two
evaluation methods (TPS vs. H-score) give equivalent results,
Pearson correlation was applied. The Wilcoxon rank-sum test
was applied to correlate the site of the recurrent tumor and DLL3
expression. To analyze for correlation of DLL3 expression with
clinicopathological characteristics, Fisher’s exact test was used.
Kaplan–Meier curves were used to illustrate OS in dependency
of DLL3 expression and statistically proved by log-rank tests. A
p-value of <0.05 was considered significant.
Immunohistochemistry (IHC)
IHC staining was performed according to the manufacturer’s
instructions, using the Ventana Discovery (Ventana Medical
System) automated staining system. In brief, slides were
incubated with the primary antibody DLL3 (clone SP347,
Ventana, SN 678, RTU). Representative tumor blocks from FFPE
tissue were cut in 4-µm thick sections.
DLL3 staining was considered positive if staining was
membranous in at least 1% of tumor cells. Protein expression
of DLL3 was assessed in two different ways: on the one hand by
estimating the percentage of positive tumor cells from all tumor
cells (tumor proportion score, TPS, range 0–100%) as previously
described (5) and, on the other hand, semi-quantitatively using
the H-score method according to Yan et al. by converting the
staining intensity (SI) (range 0–3) and the TPS (range 0–100)















Time span between diagnosis and last follow-up (days)
Min. 13 121
Max. 2.728 1.436
Chemotherapy regime (partially known)
Cisplatin + etopside 14/23 (60.9%) 8/16 (50%)
Carboplatin + etopside 9/23 (39.1%) 8/16 (50%)
Mean duration (days) 87.2 90.9
Min. duration (days) 30 30
Max. duration (days) 284 284
Palliative intention 21/23 15/16 (94%)
Adjuvant intention 1/23 0
Neoadjuvant intention 1/23 1/16 (6%)











Primary tumor + recurrent
tumor same site
14 10




DLL3 expression (chemonaive vs. chemorelapsed sample)
TPS 0% 4 vs. 6
TPS <1–49% 10 vs. 5
TPS ≥50% 16 vs. 19
H-Score 0 4 vs. 6
H-Score <150 16 vs. 8
H-Score ≥150 10 vs. 16
DLL3 expression dynamics
Stable expression 19 (63.3%) with TPS vs.
17 (56.6%) with H-Score
Higher expression in
chemonaive sample




7 (23.3%) with TPS vs. 9
(30%) with H-Score
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to a H-score (range, 0–300) (10). SI was indicated as strongly
positive (SI 3), moderately positive (SI 2), weakly positive (SI 1)
and negative (SI 0). To dichotomize samples into positive and
negative staining, TPS < 50% and H-score≤ 150 were defined as
DLL3 low expression (DLL3-low), and TPS ≥ 50% and H-score
> 150 were defined as DLL3 high expression (DLL3-high) (5, 10).
RESULTS
Expression Pattern of DLL3 Protein in
Unpaired Chemorelapsed SCLC Samples
In seven cases of the whole cohort, we had solely chemorelapsed
samples without a chemonaive counterpart. Of these, from three
patients, we had one sample each (only deriving from the primary
site), and from four patients, we had several (up to four) samples
deriving from the primary site as well as from distant metastases.
From the three cases with one sample, two were DLL3-high
and one was DLL3-low, assessed by TPS. From the four cases
with several samples, three (75%) showed a concordant DLL3
expression between the samples (two DLL3-low, one DLL3-
high), and the other one showed high-DLL3 expression in the
primary tumor and low-DLL3 expression in the metastatic site.
Considering only the staining result of the first sample of each
patient, four were DLL3-high and three DLL3-low. One of the
two cases with concordant DLL3-low expression derived from an
autopsy so that loss of expression may originate from autolysis.
Expression Pattern of DLL3 Protein in
Paired Chemonaive Primary and
Metastatic SCLC Samples
Three of the five cases with paired chemonaive primary and
metastatic SCLC samples showed a concordant DLL3-high
FIGURE 1 | Comparison of DLL3 expression in paired chemonaive-chemorelapsed SCLC samples. (A) DLL3 expression assessed by H-score. (B) DLL3 expression
assessed by TPS. (C) Pearson correlation showing application of TPS and H-score on chemonaive SCLC samples. (D) Pearson correlation showing application of
TPS and H-score on chemorelapsed SCLC samples.
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staining pattern, and in two cases, we observed a high-DLL3
expression in the primary tumor and a low expression in
the metastatic site, assessed by TPS. One case derived from
an autopsy, and here, we investigated four samples deriving
from different sites (adrenal, bone, liver, contralateral lung), all
showing concordant low DLL3 expression. Here, concordant low
expression might also be due to autolytic changes of the tissue.
Expression Pattern of DLL3 Protein in
Paired Chemonaive-Chemorelapsed SCLC
Samples
Considering only the chemonaive group, using the H-score
method, 20 (66.6 %) out of 30 samples were DLL3-low, and
10 (33.3%) were DLL3-high. Out of the DLL3-low samples,
four were negative (H-score 0). In the chemorelapsed group,
14 (46.6 %) were DLL3-low and 16 (53.3%) were DLL3-high.
Here, out of the DLL3-low samples, 6 were negative (H-score
0). DLL3 expression between the chemonaive and chemorelapsed
groups was not significantly different (Wilcoxon signed-rank test
p = 0.809; Figure 1A). Concordant staining, either DLL3-low
or DLL3-high in paired chemonaive-chemorelapsed specimens,
was observed in 17 out of 30 (56.6%) SCLCs. From those, in 11
cases (64.7%), both samples were DLL3-low, and 6 (35.9%) were
DLL3-high. In 13 cases (43.4%) staining was not concordant,
meaning that, in 9 cases, the chemonaive sample was DLL3-low
and the chemorelapsed sample was DLL3-high (“DLL3 up”) and
that in 4 cases, the chemonaive sample was DLL3-high, and the
chemorelapsed sample was DLL3-low (“DLL3 down”).
FIGURE 2 | Exemplary pictures of DLL3 staining patterns in paired chemonaive (left) and chemorelapsed (right) SCLC samples. (A) Both high DLL3 expression (TPS
> 50%, H-score > 150), (B) Both low DLL3 expression (TPS < 50%, H-score < 150), (C) “DLL3 up” [low expression in chemonaive sample (TPS < 50%, H-score <
150) and high expression in chemorelapsed sample (TPS > 50%, H-score > 150)], (D) “DLL3 down” [low expression in chemorelapsed sample (TPS < 50%, H-score
< 150) and high expression in chemonaive sample (TPS > 50%, H-score > 150); original magnification ×40].
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With regard to TPS, 14 (46.6%) chemonaive samples
were DLL3-low, and 16 (53.4%) were DLL3-high. In the
chemorelapsed group, 11 (36.6%) samples were DLL3-low and
19 (63.3%) were DLL3-high. Negative samples (TPS <1%)
within DLL3-low samples were identical to evaluation with
H-score (4 in the chemonaive and 6 in the chemorelapsed
groups, respectively). Again, DLL3 expression between the
chemonaive and chemorelapsed group was not significantly
different (Wilcoxon signed-rank test p = 0.706; Figure 1B).
In the chemonaive group, mean TPS was 52.2%, ranging
from 0 to 100%. In the chemorelapsed group, mean TPS was
57.6%, ranging from 0 to 100%. With regard to expression
dynamics, 7 out of 30 samples (23.3%) showed equally low
DLL3 expression, and 12 (40%) showed equally high expression,
meaning that, in 63.3%, TPS was stable between chemonaive and
chemorelapsed samples. In 36.7% (n = 11), DLL3 expression
between the matched samples was different. In 7 cases (23.3%),
the chemorelapsed sample had a high TPS, and the chemonaive
counterpart a low TPS (DLL3 up), and in 4 cases (13.3%)
the dynamic was the other way around (DLL3 down). DLL3
expression data are summarized in Table 1, and representative
images of DLL3 protein expression assessed by IHC are provided
in Figure 2.
Two of the cases originated from autopsies. Of these, one case
showed a DLL3-down expression pattern assessed with the H-
score method as well as with TPS. Again, this could be due to
autolytic changes of the tissue. However, the other case showed
an equally low expression without the chemorelapsed sample
being completely negative (TPS 20%, SI2). Therefore, it cannot be
stated in general that DLL3 expression is lost in autopsy material.
To assess both evaluation methods, we correlated TPS and H-
score. Pearson correlation provided a linear dependency (PCC
0.939 for chemonaive samples, PCC 0.65 for chemorelapsed
samples, Figures 1C,D), which proved that both methods were
equally applicable. Because the TPS is easier to use in everyday
diagnostic practice and probably shows less interobserver
variability, only TPS was used for further statistical analysis.
We next evaluated if there was a correlation between tumor
site and DLL3 expression. We found no significant differences
between local pulmonal and distant recurrences (Wilcoxon rank-
sum test p= 0.32; Figure 3).
Correlation of DLL3 With
Clinicopathological Characteristics in the
Paired Chemonaive-Chemorelapsed SCLC
Cohort
There was no significant correlation of DLL3 expression level
estimated in chemonaive samples with regard to gender, T-
status, N-status, M-status, UICC-status, or time to recurrence.
The only significant result was shown with regard to age: DLL3-
high SCLCs were more frequent in younger patients (median age
57 years) and SCLC with low DLL3 expression more frequent
in older patients (median age 67) (p = 0.024) (Table 2). We
performed the same analysis for the DLL3 expression level
estimated in chemorelapsed samples and, however, found no
FIGURE 3 | DLL3 expression in chemorelapsed samples in dependency of
site of recurrent tumor.
significant result for any of the above mentioned parameters
(not shown).
Correlation of DLL3 With OS in the Paired
Chemonaive-Chemorelapsed SCLC Cohort
The median age of this subcohort was 63 years (range, 47–79),
20 (66.6%) were male, 10 (33.3%), were female. From 23 out of
the 30 patients, data concerning survival status was available. The
median follow-up time for the patients with SCLCs was 354 days
(range, 121–1,436). At the time of last follow-up, 15 patients were
deceased and eight were alive.
We analyzed whether DLL3 expression (TPS low vs. high)
in chemorelapsed or chemonaive samples could predict OS.
Although results are not significant, Kaplan–Meier curves show
a trend for better OS if DLL is highly expressed in chemorelapsed
samples (log-rank p = 0.57) and less expressed in chemonaive
samples (log-rank p= 0.42) (Figures 4A,B), whereas a low DLL3
status in chemorelapsed samples and a high DLL3 expression
status in chemonaive samples seem to be more unfavorable.
Next, we aimed to analyze if the dynamics of DLL3 expression
during therapy has an impact on OS. As the above mentioned
results already suggest, upregulation of DLL3 expression in
matched samples after therapy reveals a trend for a better
OS, whereas the worst survival rates were seen in cases with
a downregulated DLL3 expression (log-rank test p = 0.56;
Figure 4C). Survival curves indicating cases in which DLL3
expression stayed stable, either both low or high, lay in between
the two curves indicating an upregulated or downregulated
DLL3-status and show also a trend for a more favorable survival
in high DLL3 expressing tumors.
DISCUSSION
SCLC is one of the most aggressive tumors with so far very
limited therapeutic options (5, 9). Essentially all patients with
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TABLE 2 | Association analysis between DLL3 expression assessed in chemonaive samples and clinicopathological characteristics of paired chemonaive-chemorelapsed
SCLC cohort.
DLL3 expression assessed in
chemonaive sample
Total TPS ≧ 50% TPS < 50% p-value
(n = 30) (n = 16) (n = 14)
Gender 0.26
Male 20 (66.7%) 9 (56.2%) 11 (78.6%)
Female 10 (33.3%) 7 (43.8%) 3 (21.4%)
Age 0.024
Missing 1 1 0
Median (IQR) 65 (57, 70) 57 (55, 68) 67 (61, 75)
T-Stage 0.58
Missing 16 8 8
T(1, 2) 4 (28.6%) 3 (37.5%) 1 (16.7%)
T(3,4) 10 (71.4%) 5 (62.5%) 5 (83.3%)
N-Status 1
Missing 16 8 8
N– 2 (14.3%) 1 (12.5%) 1 (16.7%)
N+ 12 (85.7%) 7 (87.5%) 5 (83.3%)
M-Status 1
Missing 16 8 8
M– 4 (28.6%) 2 (25.0%) 2 (33.3%)
M+ 10 (71.4%) 6 (75.0%) 4 (66.7%)
UICC-Stage 1
Missing 16 8 8
<IV 4 (28.6%) 2 (25.0%) 2 (33.3%)
IV 10 (71.4%) 6 (75.0%) 4 (66.7%)
Time to recurrence (months) 0.693
Missing 1 0
Mean (SD) 12.8 (11.6) 10.4 (7.6) 15.4 (14.5)
Median (IQR) 8 (5, 16) 8 (6, 14) 8.5 (4, 23.5)
extensive-stage SCLC and the majority of patients with limited-
stage SCLC suffer relapse within months of completing initial
standard therapy (11). As SCLC is rarely biopsied following
the initial diagnosis, dynamics of expression of therapeutically
relevant biomarkers in relapsed disease are poorly understood.
Because DLL3 is largely expressed in SCLC and regarded as a
potential biomarker for response to Rova-T treatment (8), we
aimed to investigate DLL3 expression in chemorelapsed SCLC
samples and to compare its expression with matched chemonaive
SCLC samples, correlate its expression with clinicopathological
data, and perform survival analysis stratified according to DLL3-
high or DLL3-low status and dynamics of DLL3 expression
during the course of therapy. Possible differences in expression
may further indicate if chemonaive or chemorelapsed SCLC
specimens should be investigated in cases of a planned therapy
with Rova-T. To our knowledge, there are hardly any published
studies that investigated DLL3 expression in chemorelapsed
SCLC samples and paired chemonaive-chemorelapsed SCLC
samples, respectively.
In line with data from the literature, we as well found
DLL3 expression in the majority of our SCLC samples.
The evaluation method to assess DLL3 expression is
not standardized, and there are so far no international
standards for cut-off values to determine expression of
DLL3 (4).
When comparing the DLL3 expression data of our study
with those from the literature, it is important to consider not
only the evaluation method, but also the diversity of the DLL3
antibodies used. Brcic et al. (12) investigated four different DLL3
antibodies (VenA (clone SP347; Ventana, Roche, Tucson, AZ,
USA), NovA (NBP2–24669; Novus Biological, Littleton, CA,
USA), TherA (PA5–26336; Thermo Fisher Scientific, Waltham,
MA, USA), and AbcA (ab103102; Abcam, Cambridge, MA,
USA)) for their reliability to detect DLL3 expression in high-
grade neuroendocrine tumors of the lung. Comparison of VenA
[the antibody used in the current study and in the clinical trial
(5)] with the other three antibodies demonstrated poor results for
overall agreement, positive and negative agreement, and Kappa
values. The authors concluded that using VenA as a reference
antibody, none of the other three antibodies can reliably be
used for the DLL3 test. This, of course, makes comparison of
DLL3 expression data between studies difficult. Table 3 gives an
overview of some recent studies dealing with DLL3 expression
in SCLC, including their cohort sizes, evaluation methods, used
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FIGURE 4 | Overall survival according to DLL3 expression status. (A) Kaplan–Meier curves stratified according to DLL3-high or DLL3-low status assessed with TPS in
chemorelapsed specimens (log-rank p = 0.57). (B) Kaplan–Meier curves stratified according to DLL3-high or DLL3-low status assessed with TPS in chemonaive
specimens (log-rank p = 0.42). (C) Kaplan–Meier curves stratified according to dynamics of DLL3 expression in the course of therapy. Persisted DLL3-low was defined
as TPS < 50% in chemonaive and chemorelapsed samples, persisted DLL3-high was defined as TPS ≥50% in chemonaive and chemorelapsed samples, “up” was
defined as a switch from TPS < 50% to ≥ 50%, and “down” was defined as a switch from TPS ≥50% to <50% in the course of therapy (log-rank test p = 0.56).
DLL3 antibodies, used cutoffs, and assessed expression data of
DLL3 in SCLC.
We assessed DLL3 expression in two different ways, using the
H-score and TPS, both known from prior studies (5, 10). We
adopted 50% as the cutoff for TPS from a phase I trial conducted
by Rudin et al. (5) and, with that, found expression of DLL3
in majority of chemonaive samples (86.6%) out of which 46.6%
were DLL3-low and 53.4% DLL3-high. In the study from Rudin
et al. (5), the range was higher with 74.4% being highly positive
(29/39) and 25.6% (10/39) being weakly positive. The same
cutoff was used by Tanaka et al., who investigated 63 presumably
chemonaive SCLC samples and found 83% (52/63) positive for
DLL3 with 20 samples (32%) being highly positive (3). The data
in the literature vary; nevertheless, overall, a quite high rate of
highly DLL3 expressing SCLC can be observed. In the group
of chemorelapsed SCLC, we found similar DLL3 expression to
that in the chemonaive group with 80% being positive, but with
a slightly higher proportion of DLL3-high cases (63.3%, 19/30).
DLL3 expression between chemonaive and chemorelapsed was
stable in more than half of the cases (63.3%) and shifted from
low to high or vice versa in 36.7%. However, DLL3 expression
between chemonaive and chemorelapsed SCLC samples was not
significantly different (Wilcoxon signed-rank test p = 0.706;
Figure 1B) indicating no essential therapy-induced differences.
For evaluation with H-score, we adopted the cutoff of
150 from Yan et al. (10), who investigated 335 presumably
chemonaive (de novo) SCLC samples and found a low expression
(H-score≤ 150) in 37.6% and a high expression (H-score > 150)
in 62.4%. We found contrasting results with this method with a
low expression in 66.6% (20/30) in the chemonaive group and
a high expression in 33.3% (10/30) in the chemorelapsed group.
In the chemorelapsed group instead, expression data were then
again similar to those from above mentioned study with a shift
to more highly positive SCLC cases [(53.3%, 16/30) vs. 46.6%
(14/30) DLL3 low expressing samples]. However, the data are
hardly comparable due to the significant differences in the size
of the cohorts (335 vs. 30).
Concordant staining in paired chemonaive-chemorelapsed
specimens, either both DLL3-low or DLL3-high, was found in
only approximately half of the cases (56.6%), meaning that a
significant portion (43.4%) showed a shift of DLL3 expression
during course of therapy. However, also with this method, we
found no significantly different DLL3 expressions between the
two groups (Wilcoxon signed-rank test p= 0.809; Figure 1A).
With both evaluation methods, the proportion of matched
samples showing deviating DLL3 expression, meaning a shift
from low to high expression or vice versa, during course of
therapy was considerable (43.4% with H-score, 36.7% with
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TABLE 3 | Overview of recent studies on DLL3 expression in SCLC.
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TPS). This indicates that DLL3 expression might be influenced
by therapy and cannot be considered as stable. Unlike other
predictive biomarkers, such as, e.g., PD-L1 with a required TPS
of 50% for therapy of NSCLC with Pembrolizumab, so far, a
high (≥50%) DLL3 expression of SCLC is not implemented as a
prerequisite for therapy with Rova-T. However, if this were the
case, our data demonstrate that it does matter which samples
are chosen to assess DLL3 expression. There is only a little
literature concerning DLL3 expression in paired chemonaive-
chemorelapsed SCLC samples. Rojo et al. (16) investigated, in
addition to a huge number of independent SCLC samples, also
36 paired SCLC samples, defining “paired” as two specimens
from the same patient and same primary disease site or as a
first specimen obtained at diagnosis and the second obtained at
relapse/recurrence. Of these, only two samples corresponded to
paired chemonaive-chemorelapsed samples as we had examined.
Moreover, they used a different cutoff than we did with
≥25% positive tumor cells defined as positive DLL3 expression
(Table 3). With that, they found 88% concordance between
paired specimens without specifically addressing the paired
chemonaive-chemorelapsed samples. Due to the significant
deviation in size of the cohorts, results of this study are hardly
comparable with our results.
To our knowledge, the above mentioned study by Yan et al.
(10) is the only one using theH-scoremethodwith a cutoff of 150.
Furthermore, combining a four-level SI and TPS to a H-score
should show higher interobserver variability than just using TPS.
We, therefore, assessed the two evaluation methods, and after
Pearson correlation provided a linear dependency that indicated
equality, we have then focused on TPS for further analyses.
We next investigated if the site of the biopsied recurrent
tumor has an impact on DLL3 expression. In 33.3% (10/30)
chemorelapsed tissue derived from local pulmonal recurrences
and in 63.3% (19/30) from distant metastases. Concordant with
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the literature (3, 10), we found no significant differences of
DLL3 expression between local pulmonal and distant recurrences
(Wilcoxon rank-sum test p = 0.32; Figure 3). Yan et al., for
instance, compared intertumoral expression of DLL3 on the basis
of 37 paired biopsies of primary and metastatic sites and found
concordant staining in all cases (10).
Apart from age when considering the chemonaive samples, we
found no association of DLL3 expression with clinicopathological
data in our cohort (Table 2). Our observation that DLL3
expression actually does not associate with clinicopathological
data broadly fit with those from the literature. For instance,
Tanaka et al. (3) also found no significant association between
DLL3 expression and age, sex, smoking history, or disease stage,
and Yan et al. (10) found no significant association with age,
distant metastasis status, or TNM stage. In the latter study, DLL3
expression was higher in TTF-1 expressing SCLC samples (p =
0.006), smokers (p= 0.023), and males (p= 0.041), whereas high
DLL3 expression was associated with female sex (p = 0.03) in a
study conducted by Xie et al. (13). Furata et al. found that DLL3-
high expression (defined as TPS ≥ 75%) was significantly more
prevalent in patients with lymph node metastases and advanced
c-stage (15). These few significant correlations found in our
study and in the literature are, due to their diversity, primarily
a coincidence and might not have a causal relationship.
We next investigated if DLL3 expression has an impact on
OS. Kaplan–Meier curves do not show significant results, but a
trend for a better OS if DLL is highly expressed in chemorelapsed
samples (log-rank p = 0.57) and low expressed in chemonaive
samples (log-rank p= 0.42) (Figures 4A,B), whereas a low DLL3
status in chemorelapsed samples and a high DLL3 expression
status in chemonaive samples seem to be more unfavorable.
Several other studies also analyzed the relationship of DLL3
expression and OS, and the corresponding results are partly
contradictory. Some studies found no statistically significant
difference of OS between DLL3 low and high expressing tumors
(3, 15), whereas Regzedmaa et al. found that high expression
of DLL3 assessed on chemonaive SCLC correlated significantly
with poorer patient outcomes (p = <0.001) (8). Yan et al. also
found that patients with chemonaive SCLC having a high DLL3
expression level exhibited a lower OS compared with patients
with DLL3-low expressing SCLC (p = 0.007). In this study,
expression of DLL3 and TTF-1 was investigated in combination,
and additionally, it was found that the group of SCLC with
low expression of DLL3 in combination with missing TTF-1
expression showed improved OS (10). Huang et al. also found
a high level of DLL3 to be correlated with low OS rate (p <
0.01) (14). Despite lacking significance, our survival curves also
indicate that there is a trend for better survival if chemonaive
samples show low DLL3 expression (Figure 4B). Xie et al. found
that high DLL3 expression was associated with better OS in
SCLC (p= 0.049). At first glance, the results seem contradictory.
However, in this study, only a few cases showed low DLL3
expression, and after adjusting for age, tumor size, and stage,
DLL3 expression was no longer associated with OS (13).
Due to our samples being matched, we then analyzed if
the dynamics of DLL3 expression in the course of therapy
associates with survival. As the above mentioned results
already suggest, upregulation of DLL3 expression in matched
samples after therapy reveals a trend for better overall survival,
whereas the worst survival rates were seen in cases with
a downregulated DLL3 expression (log-rank test p = 0.56;
Figure 4C). Survival curves indicating cases in which DLL3
expression was concordant in chemonaive and chemorelapsed
samples, either both low or high, lay in between the two
curves, indicating survival in dependency of an upregulated
or downregulated DLL3-status. Here, a trend that stable high
expression is associated with a more favorable survival than
stable low expression can be derived. This might suggest that
DLL3 expression assessed in chemorelapsed samples is more
meaningful regarding OS due to beforehand we could show that
a low expression in chemonaive samples and a high expression
of DLL3 only in chemorelapsed samples indicated a better OS
(Figures 4A,B).
In a study from Tendler et al. (7), it was found that
subjects with Notch1 low expressing chemorelapsed SCLC
samples showed a better prognosis and higher sensitivity to
chemotherapy. Assuming that Notch1 and DLL3 are opponents
during the evolution of SCLC, one could expect a high DLL3
expression if Notch 1 shows a low expression. Thus, our result
for a trend for better prognosis in DLL3 high expressing
chemorelapsed SCLC is in line with that of Tendler et al.
To our knowledge, our study is the first investigating
DLL3 expression in a large cohort of paired chemonaive-
chemorelapsed SCLC samples, which is why our results
concerning OS in relation to the dynamics of DLL3 expression
cannot be compared with data in the literature. Our survival data
is not significant. This might be due to the relatively small cohort
size, which, at the same time, represents a limitation of our study.
However, against the background that, in most cases, recurrent
SCLC is not biopsied at all, our cohort is exceptional. Another
limitation of our study is that recent literature (17, 18) on DLL3
seems to diminish its value as a potential therapeutic agent, which
also weakens the value of the present work.
To sum up, the current study delivers, for the first time,
data concerning DLL3 expression in a large cohort of rare
paired chemonaive and chemorelapsed SCLC samples, which
is exceptional due to relapsed SCLC are usually not being
biopsied. However, investigation of chemorelapsed tumor tissue
is essential because it might provide hints why early recurrences,
characteristic for SCLC, occur. As the first, we show that,
in a large proportion of paired chemonaive-chemorelapsed
SCLC samples, DLL3 expression is not stable during the
course of therapy, indicating therapy-associated alterations.
This demonstrates that it is worth assessing protein expression
of biomarkers in general and here, especially of DLL3 in
chemorelapsed samples, meaning in the latest tumor tissue. This
should, at the same time, be an incentive to gain tumor tissue by
biopsy in relapses. Due to the manner of assessing expression of
DLL3 not being standardized, we tested two evaluation methods
and applied TPS and H-score. Both approaches delivered
comparable results, but because TPS should be more practical in
routine diagnostics than the H-score method, we have continued
working with TPS. As in other studies, we found that the majority
of SCLC samples expressed DLL3 and also did not find any
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profound correlations with clinicopathological data or tumor
site. Concordant with data from the literature, our survival
analysis revealed a trend for a better OS if DLL is low expressed
(<50%) in chemonaive samples. Interestingly, this does not seem
to apply to chemorelapsed SCLC because, for those, we could
observe a trend for amore favorable survival in the event of a high
expression (≥50%). In line with that, cases showing a shift from
a low to a high expression of DLL3 during the course of therapy
indicated the most favorable survival data. These results should
not be overstated due to the size of our cohort not being powered
to detect association with survival data. However, the study
definitely shows the importance of research of chemorelapsed
tumor tissue.
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